Satraplatin in the treatment of hormone-refractory metastatic prostate cancer

Satraplatin is an orally bioavailable platinum chemotherapeutic agent under development for several cancer types, including hormone-refractory prostate cancer (HRPC). Satraplatin is being developed for the treatment of men with chemorefractory HRPC for several reasons: 1) relative ease of administra...

Descripción completa

Detalles Bibliográficos
Autores principales: Armstrong, Andrew J, George, Daniel J
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376074/
https://www.ncbi.nlm.nih.gov/pubmed/18473011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376074/
https://www.ncbi.nlm.nih.gov/pubmed/18473011

Ejemplares similares